Effect of Phenylephrine Versus Norepinephrine on Venous Return

Sponsor
Algemeen Ziekenhuis Maria Middelares (Other)
Overall Status
Unknown status
CT.gov ID
NCT03872570
Collaborator
(none)
40
1
2
12.5
3.2

Study Details

Study Description

Brief Summary

Induction of general anesthesia often induces a decrease in the mean arterial blood pressure (MAP) caused by arterial and venous dilatation. Fluid administration is conventionally used to increase the patient's total blood volume, but is often associated with multiple adverse events such as postoperative edema.

Arterial hypotension can also be treated by vasopressor agents such as norepinephrine and phenylephrine which mainly increase the blood pressure by arterial vasoconstriction.

Compared to phenylephrine, norepinephrine has a shorter half-life (2 - 3 minutes) and improves the MAP by increase in cardiac contractility. In a recent study at our department it was demonstrated that besides arterial vasoconstriction, phenylephrine also improves venous return and cardiac output by venous vasoconstriction.

The aim of this study is to compare the hemodynamic effects of both vasopressor agents in patients undergoing deep inferior epigastric perforators (DIEP) flap surgery. If significant differences between both agents are demonstrated, these findings can provide an important basis for future recommendations.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

In consecutive patients scheduled for DIEP flap surgery, all hemodynamic and respiratory variables are recorded electronically for subsequent off line analysis.

A systolic blood pressure of minimal 100 mmHg will be maintained during surgery by optimization of the cardiac preload and titrated norepinephrine (1.5 µg/kg/h) or phenylephrine (15 µg/kg/h) administration. Cardiac preload optimization will be based on pulse pressure variation (PPV) measurement, which is calculated by pulse contour analysis of the radial arterial pressure curve. Following the international goal-directed fluid therapy guidelines, plasmalyte will be administrated if the PPV>11%.

The tricuspid annular plane systolic excursion (TAPSE) will be measured by transthoracic echocardiography (TTE) to evaluate the inotropic effect of norepinephrine and phenylephrine. In addition, TTE will be used to measure the cardiac output to calibrate the PPV measurements.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
Comparison of the Hemodynamic Effects of Phenylephrine and Norepinephrine in Patients Undergoing Deep Inferior Epigastric Perforator (DIEP) Flap Surgery.
Actual Study Start Date :
Jun 1, 2019
Anticipated Primary Completion Date :
Jun 1, 2020
Anticipated Study Completion Date :
Jun 15, 2020

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: phenylephrine

starts at 15 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg

Drug: Phenylephrine
intravenous administration

Active Comparator: norepinephrine

starts at 1.5 µg/kg/h phenylephrine and titrated to main a minimal systolic blood pressure of 100 mmHg

Drug: Norepinephrine
intravenous administration

Outcome Measures

Primary Outcome Measures

  1. pulse pressure variation [perioperative]

    the evolution of the pulse pressure variation in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration

Secondary Outcome Measures

  1. mean arterial blood pressure [perioperative]

    the evolution of the mean arterial blood pressure in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration

  2. cardiac output [perioperative]

    the evolution of the cardiac output in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration

  3. stroke volume (variation) [perioperative]

    the evolution of the stroke volume (variation) in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration

  4. heart rate [perioperative]

    the evolution of the heart rate in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration

  5. ventilation frequency [perioperative]

    the evolution of the ventilation frequency in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration

  6. end-tidal CO2 [perioperative]

    the evolution of the end-tidal CO2 in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration

  7. tidal volume [perioperative]

    the evolution of the tidal volume in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration

  8. TAPSE [perioperative]

    the evolution of the tricuspid annular plane systolic excursion in a time course of 20 minutes after the start of phenylephrine/norepinephrine administration

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 85 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adult

  • patients scheduled for DIEP flap surgery

Exclusion Criteria:
  • unwilling or unable to grant written informed consent

  • contra-indications for phenylephrine or norepinephrine

  • cardiac arrhythmia

  • no necessity for pharmacological blood pressure management

Contacts and Locations

Locations

Site City State Country Postal Code
1 General Hospital Maria Middelares Ghent Oost-Vlaanderen Belgium 9000

Sponsors and Collaborators

  • Algemeen Ziekenhuis Maria Middelares

Investigators

  • Principal Investigator: Alain F Kalmar, MD, PhD, Maria Middelares Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Dr. Alain Kalmar, MD, PhD, Staff Anesthesist, Algemeen Ziekenhuis Maria Middelares
ClinicalTrials.gov Identifier:
NCT03872570
Other Study ID Numbers:
  • MMS.2019.008
First Posted:
Mar 13, 2019
Last Update Posted:
Oct 11, 2019
Last Verified:
Oct 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Dr. Alain Kalmar, MD, PhD, Staff Anesthesist, Algemeen Ziekenhuis Maria Middelares
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 11, 2019